Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed common stock at a price of $246.42 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 9, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
- The sale was executed at a price of $246.42 per share.
- The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
- Following the transaction, Sandercock directly owns 96,812 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding a stock sale by an executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Sales by company executives are a normal part of corporate activity. The use of a 10b5-1 plan suggests the executive is selling shares in a pre-planned manner to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date the Rule 10b5-1 plan was adopted. |
| September 9, 2024 | Date of the stock sale transaction. |
| September 10, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.